Crx-4KV

Crx-4KV is a **discovery-stage small-molecule antiviral candidate** from **Cryptyx Biosciences** being developed for **Respiratory Syncytial Virus infection**. The company describes it as a natural product-derived small molecule from its cryptic biosynthetic gene cluster platform and highlights an **unprecedented chemotype** with reported **approximately 20-fold greater potency than ribavirin** in company materials. No specific molecular target or detailed mechanism of action has been publicly disclosed, so it is best characterized at present as an investigational RSV-directed small molecule with undisclosed target biology.